Hormonal
Combining GLP-1 RAs with basal insulin provides superior glycemic management and cardiorenal protection compared to using either therapy alone, while mitigating the side effects of high-dose GLP-1 RAs.
If you are struggling to control your blood sugar with just a GLP-1 shot (like Ozempic) or just basal insulin, combining them is often the most effective strategy. New 'fixed-ratio' combination pens allow you to inject both medications in a single shot. This approach lowers your A1C more effectively than either drug alone, protects your heart and kidneys, and often reduces the side effects (like nausea) associated with high doses of GLP-1 RAs.
Numerous studies have shown that combined GLP-1 RA/basal insulin therapy provides effective glycemic management and cardiorenal protection, with reduced hypoglycemia risk
Why this rating
Supported by numerous randomized trials and fixed-ratio combination (FRC) product approvals.
Source
The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
Janet B. McGill et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01569-8
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) are dependent on residual beta-cell function and insulin availability, meaning that as Type 2 Diabetes progresses and beta-cell function declines, GLP-1 RAs lose efficacy and patients eventually require insulin therapy.Good
- Discontinuation of GLP-1 RA therapy is associated with significant weight regain, loss of cardiorenal protection, and an increased risk of Major Adverse Cardiovascular Events (MACE).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →